Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The basic helix–loop–helix transcription factor is a class of dimeric transcriptional regulators defined by a protein motif with two α-helices separated by a loop, including a run of basic amino acids critical for DNA binding. Members of this family regulate gene transcription through binding to E-box DNA motifs, and they participate in the control of essential biological processes such as development, cell proliferation, tissue specification, metabolism, circadian rhythms, and stress responses. Functionality is often mediated via homo- or hetero-dimerization, and further specified by associated domains such as leucine-zippers (bHLHZ) or PAS domains (bHLH-PAS). While the family as a whole is not a specific drug target, individual bHLH proteins (e.g., c-Myc, HIF-1α, AHR, CLOCK) are key regulatory nodes and validated therapeutic targets implicated in various diseases, especially cancer and developmental disorders.
(for drugs targeting individual bHLH proteins) - Inhibit DNA-binding activity - Disrupt dimerization - Block protein expression or stability - Modulate ligand-dependent activation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Basic helix–loop–helix transcription factor (bHLH).